- Investing Ideas
- /
- Global Pharmaceuticals & Biotech High Insider Buying
Global Pharmaceuticals & Biotech High Insider Buying
UPDATED Mar 11, 2024
Stocks with high levels of insider buying the past 3 months and good analyst coverage.
160 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| DVYSRDevyser Diagnostics | kr93.60 | -0.4% | 21.6% | kr1.5b | kr115.39 | PS9x | E99.3% | n/a | ||
| BCABBioAtla | US$2.85 | 2.9% | 15.9% | US$136.6m | US$12.25 | PB1.4x | E7.2% | n/a | ||
| XSPRAYXspray Pharma | kr44.10 | 5.5% | -41.1% | kr1.4b | kr107.00 | PB2x | S86.7% | n/a | ||
| NGENNervGen Pharma | CA$3.00 | -7.7% | 72.4% | CA$179.5m | CA$5.00 | PB35.1x | n/a | n/a | ||
| HITIHigh Tide | CA$2.28 | -3.4% | 51.0% | CA$176.8m | CA$5.95 | PB1.4x | E109.9% | n/a | ||
| IMUXImmunic | US$1.36 | -9.3% | -22.7% | US$128.6m | US$6.50 | PB4.2x | E54.9% | n/a | ||
| GALTGalectin Therapeutics | US$1.97 | -4.4% | 2.6% | US$124.3m | US$11.00 | PE-2.7x | E55.5% | n/a | ||
| ARXAroa Biosurgery | AU$0.54 | -6.1% | -47.5% | AU$183.8m | AU$1.02 | PS3x | E114.4% | n/a | ||
| YSYS Biopharma | US$0.68 | 11.2% | -90.8% | US$120.3m | US$5.17 | PS1.6x | E68.3% | n/a | ||
| DXRXDiaceutics | UK£1.02 | 5.7% | -8.1% | UK£85.7m | UK£1.67 | PE14286.4x | E59.5% | n/a | ||
| IBT BInfant Bacterial Therapeutics | kr79.80 | -2.2% | 53.5% | kr1.1b | n/a | PB3.5x | n/a | n/a | ||
| OTLKOutlook Therapeutics | US$0.35 | -11.7% | -66.1% | US$101.7m | US$2.22 | PE-1.8x | E62.1% | n/a | ||
| 6628Transcenta Holding | HK$1.90 | -15.6% | -25.2% | HK$793.7m | HK$8.48 | PS6.3x | E2.3% | n/a | ||
| ACOGAlpha Cognition | CA$0.89 | 18.7% | 128.2% | CA$133.4m | CA$1.00 | PE-8.2x | n/a | n/a | ||
| 950Lee's Pharmaceutical Holdings | HK$1.29 | -3.7% | -15.1% | HK$759.6m | HK$1.00 | PE19.5x | S13.5% | 1.2% | ||
| ACHVAchieve Life Sciences | US$4.35 | -0.9% | -4.0% | US$92.1m | US$22.57 | PB22.8x | E50.1% | n/a | ||
| ACRSAclaris Therapeutics | US$1.22 | -3.9% | -85.0% | US$91.5m | US$6.17 | PS2.8x | E-11.1% | n/a | ||
| GRINGrown Rogue International | CA$0.65 | -5.8% | 348.3% | CA$116.5m | n/a | PS3.8x | n/a | n/a | ||
| GSSGenetic Signatures | AU$0.69 | -2.1% | -12.1% | AU$128.7m | n/a | PS8x | E74.6% | n/a | ||
| SAKARSakar Healthcare | ₹365.00 | -3.2% | 63.9% | ₹6.9b | n/a | PE55.7x | n/a | n/a | ||
| PAAPharmAust | AU$0.32 | 8.6% | 266.3% | AU$123.0m | n/a | PS33.2x | n/a | n/a | ||
| RZLTRezolute | US$1.95 | 9.6% | -14.1% | US$79.3m | US$8.50 | PB0.8x | E21.3% | n/a | ||
| CSBRChampions Oncology | US$5.67 | 0.4% | 31.6% | US$76.4m | US$9.00 | PS1.5x | S12.4% | n/a | ||
| ASMBAssembly Biosciences | US$12.78 | -5.0% | -18.1% | US$73.5m | US$36.00 | PB1.7x | E-9.4% | n/a |